We are discovering cutting-edge radiochemical methods to create new radiotracers to advance brain imaging research in:
- Alzheimer’s disease
- autism spectrum disorders
- brain cancers
- Parkinson’s disease
- traumatic brain injuries.
Results You Can See
The Azrieli Centre for Neuro-Radiochemistry builds on CAMH’s pioneering work in radiochemistry over the past 30 years. CAMH researchers have developed several radiotracers commonly used in PET brain imaging globally. Using these chemical brain imaging tools, our research has helped to more accurately calculate medication doses for depression and schizophrenia, identified targets for treatments of illnesses such as postpartum depression, and enabled pharmaceutical companies and academic centres to conduct more effective drug development.
We've also used radiotracers to discover chemical brain markers that identify the risk of illnesses such as schizophrenia before they develop, with the goal of helping with early interventions.